Skip to content
Bharat Immunological & Biological Corporation logo

Bharat Immunological & Biological Corporation

524663 BSE
₹9.03

Close ·

P/E
Not meaningful: loss-making over the last twelve months
View as Markdown
MCP
Close 4 Nov 2026 ₹9.03 −11.24 −55.5% 1Y
Start ₹20.27

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare

Price-based figures at the close · TTM

ROCE
−9.27%
Debt to Equity
0.94
EPS (TTM)
−₹4.20
Book Value
—
Market Cap
—
P/E (TTM)
Not meaningful: loss-making over the last twelve months
P/B
—
ROE
−17.70%
Dividend Yield
0.00%
EBITDA
−₹15.70 Cr
52W High
₹22.61
52W Low
₹7.11

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

40 Weak

Data confidence 88/100

Category scores

Quality
34
Poor
Returns, margins, earnings quality 22% weight
Valuation
74
Strong
Cheap vs sector & own history 24% weight
Growth
1
Poor
Sales & profit trajectory 9% weight
Financial Health
12
Poor
Solvency, leverage, coverage 9% weight
Momentum
4
Poor
Trend strength, vol-adjusted 12% weight
Ownership
50
Average
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

1
  • Stock is trading at 0.41 times its book value

Weaknesses

4
  • Company has low interest coverage ratio.
  • The company has delivered a poor sales growth of 5.09% over past five years.
  • Company has a low return on equity of -22.7% over last 3 years.
  • Debtor days have increased from 39.6 to 114 days.

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallStrong Bearish1162
OscillatorsBullish162
Moving AveragesStrong Bearish1000

Key readings

RSI (14)
37.23
Neutral
MACD (12,26,9)
−0.73
Bullish
SMA (50)
11.94
Bearish
SMA (200)
15.91
Bearish

As of

Growth Rate

Annual windows: The latest annual results are more than two years old, so no annual growth is shown.

Trailing twelve months: The latest quarterly results are more than a year old.

Quarterly Results

₹ Cr

Results for the period ended Dec 2023 were due by 14 Feb 2024 and are not in this table yet.

524663 quarterly results, ₹ crore
Particulars Sep 2020Dec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023
Sales
25.36
25.2
15.62
14.22
24.7
17.43
22.04
10.48
26.48
0
7.65
0
0
Expenses
29.86
27.47
31.54
13.18
28.19
16.41
25.71
15.31
28.98
4.72
11.67
4.31
4.68
Operating Profit
−4.5
−2.27
−15.92
1.04
−3.49
1.02
−3.67
−4.83
−2.5
−4.72
−4.02
−4.31
−4.68
OPM %
−17.74%
−9.01%
−101.92%
7.31%
−14.13%
5.85%
−16.65%
−46.09%
−9.44%
—
−52.55%
—
—
Other Income
0.14
1.2
9.08
0.25
0.22
0.12
0.59
0.14
0.32
0.1
0.49
0.1
0.16
Interest
1.17
1.3
1.22
1.16
1.23
1.54
1.68
1.58
1.74
1.67
2.06
1.72
2.09
Depreciation
0.06
0.06
0.06
0.06
0.06
0.04
0.05
0.04
0.04
0.04
0.09
0.03
0.03
PBT
−5.59
−2.43
−8.12
0.07
−4.56
−0.44
−4.81
−6.31
−3.96
−6.33
−5.68
−5.96
−6.64
Tax %
−30.77%
−21.81%
−19.46%
−2642.86%
105.26%
−25%
−11.02%
−20.76%
−22.22%
−26.07%
−31.69%
−23.15%
−26.05%
Net Profit
−3.87
−1.89
−6.53
1.93
−9.36
−0.33
−4.28
−5
−3.08
−4.68
−3.88
−4.59
−4.92
EPS (₹)
−0.9
−0.44
−1.51
0.45
−2.17
−0.08
−0.99
−1.16
−0.71
−1.08
−0.9
−1.06
−1.14

Profit & Loss

₹ Cr
524663 profit and loss, annual, ₹ crore
Particulars Mar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023TTM
Sales
46
173
203
146
128
124
35
84
67
85
78
45
8
Expenses
41
164
191
143
132
111
43
93
77
106
83
63
25
Operating Profit
6
9
12
3
−4
13
−8
−9
−10
−21
−5
−18
−18
OPM %
12%
5%
6%
2.3%
−3.1%
10%
−23%
−11%
−16%
−24%
−6%
−41%
−232%
Other Income
2
1
6
1
1
1
1
4
1
2
1
3
1
Interest
0
2
6
1
6
4
1
2
5
5
6
7
8
Depreciation
1
1
1
1
1
1
0
0
0
0
0
0
0
PBT
6
7
11
2
−9
9
−8
−7
−14
−24
−10
−23
−25
Tax %
−111%
27%
42%
26%
−31%
29%
−46%
−21%
−28%
−25%
−10%
−25%
—
Net Profit
13
5
6
2
−6
7
−4
−6
−10
−18
−9
−17
−18
EPS (₹)
2.91
1.16
1.48
0.36
−1.44
1.51
−0.99
−1.34
−2.36
−4.19
−2.03
−3.95
−4.18
Div. Payout %
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
—

Balance Sheet

₹ Cr
524663 balance sheet, annual, ₹ crore
Particulars Mar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Sep 2023
Equity Capital
43
43
43
43
43
43
43
43
43
43
43
43
43
Reserves
−15
−1
−3
−2
−8
−1
−6
−12
−23
−9
62
45
36
Borrowings
7
0
−1
−9
9
0
0
32
3
27
78
70
74
Other Liabilities
45
48
52
48
24
17
16
62
103
43
29
28
35
Total Liabilities
81
90
91
80
68
59
53
125
127
104
213
186
188
Fixed Assets
9
8
7
6
6
5
5
5
4
4
116
115
115
CWIP
1
0
0
0
0
0
0
0
0
32
0
0
0
Investments
0
0
0
0
0
0
0
0
0
0
0
0
0
Other Assets
71
82
84
74
63
53
48
120
122
68
97
70
73
Total Assets
81
90
91
80
68
59
53
125
127
104
213
186
188

Cash Flow

₹ Cr
524663 cash flow, annual, ₹ crore
Particulars Mar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Operating
5
31
−12
8
−9
−17
3
−32
34
12
−42
11
Investing
0
0
0
0
1
0
−1
1
1
1
1
0
Financing
−3
0
−6
−1
−2
−3
−1
31
−34
−12
45
−15
Net Cash Flow
2
31
−18
7
−10
−20
1
−1
1
0
3
−3
Free Cash Flow
5
32
−12
8
−9
−17
3
−32
34
12
−42
11
CFO/OP
89
338
−99
229
239
−132
−32
344
−328
−56
847
−59

Ratios

524663 financial ratios, annual
Particulars Mar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Debtor Days
209
2
47
34
37
19
167
318
96
0
5
114
Inventory Days
241
87
66
84
77
2
23
67
308
56
202
13
Days Payable
316
99
70
103
26
1
6
204
259
61
5
4
Cash Conversion Cycle
134
−9
43
16
88
19
185
181
145
−5
203
122
Working Capital Days
−20
−20
21
20
28
−19
59
10
−108
−174
−227
−549
ROCE %
20%
23%
42%
9%
−8%
31%
−18%
−11%
−22%
−46%
−3%
−9%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Bharat Immunological & Biological Corporation insights

62 extracted metrics across FY08–FY24.

Shareholding Pattern

Latest filing: Mar 2024

As of Mar 2024

  • Promoters 59.25%
  • Public 39.47%
  • Others 1.28%

Pledge data not available

Change vs previous quarter

Documents

Frequently Asked Questions about Bharat Immunological & Biological Corporation

What does Bharat Immunological & Biological Corporation Ltd do?
Incorporated in 1989, Bharat Immunological and Biologicals Corporation Ltd manufactures biotechnology-based pharmaceuticals.
Where is Bharat Immunological & Biological Corporation Ltd (BIBCL) listed?
Bharat Immunological & Biological Corporation Ltd trades under code 524663 on the BSE.
Which sector does Bharat Immunological & Biological Corporation Ltd belong to?
Bharat Immunological & Biological Corporation Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the 52-week high and low of Bharat Immunological & Biological Corporation Ltd?
Over the last 52 weeks Bharat Immunological & Biological Corporation Ltd has traded between ₹7.11 and ₹22.61 as of 4 Nov 2026.
What is the Return on Equity (ROE) of Bharat Immunological & Biological Corporation Ltd?
Bharat Immunological & Biological Corporation Ltd reported a return on equity of -17.70%. Its debt-to-equity ratio is 0.94.

Company Information

Incorporated in 1989, Bharat Immunological and Biologicals Corporation Ltd manufactures biotechnology-based pharmaceuticals.

Website bibcol.com
Face Value ₹10

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/524663.md for Bharat Immunological & Biological Corporation Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month